Thanks very much, Chair.
I'd like to continue on the route that Dr. Powlowski was on. I think it's important to correct some misconceptions that we've heard here in this committee.
For instance, opioid agonist therapy and witness dosing, as Dr. Powlowski talked about, obviously is not the same thing as not having a therapeutic relationship with an individual who uses drugs and simply sending them home with 30 tablets of eight-milligram Dilaudid.
Dr. Vogel, I'll start with you, sir, if I may.
During your time in participation in the Swiss model, was that type of safe supply ever trialed in Switzerland, just giving patients eight-milligram tablets of Dilaudid in significant quantities?